Results 251 to 260 of about 1,164,667 (298)
Some of the next articles are maybe not open access.
Biomarkers: to be or not to be
Annals of the Rheumatic Diseases, 2020We read with great interest the article by van den Hoogen et al 1 describing galectin-9 (Gal-9) as a novel, easy-to-measure biomarker for the interferon (IFN) signature in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). We support the views expressed by the authors that IFN signature is an important biomarker in disease activity
Sule, Yavuz, Lars, Rönnblom
openaire +2 more sources
2015
Biomarkers are key tools and can provide crucial information on the complex cascade of events and molecular mechanisms underlying traumatic brain injury (TBI) pathophysiology. Obtaining a profile of distinct classes of biomarkers reflecting core pathologic mechanisms could enable us to identify and characterize the initial injury and the secondary ...
MONDELLO, STEFANIA, Hayes, Ronald L.
openaire +2 more sources
Biomarkers are key tools and can provide crucial information on the complex cascade of events and molecular mechanisms underlying traumatic brain injury (TBI) pathophysiology. Obtaining a profile of distinct classes of biomarkers reflecting core pathologic mechanisms could enable us to identify and characterize the initial injury and the secondary ...
MONDELLO, STEFANIA, Hayes, Ronald L.
openaire +2 more sources
Biomarkers of Immunosuppression
Critical Care Clinics, 2020It is now recognized that sepsis is not a uniformly proinflammatory state. There is a well-recognized counter anti-inflammatory response that occurs in many patients. The timing and magnitude of this response varies considerably and thus makes its identification and manipulation more difficult.
Abinav K, Misra +2 more
openaire +2 more sources
Biomarkers in pediatrics: Children as biomarker orphans
PROTEOMICS – Clinical Applications, 2010AbstractBiomarkers have enormous potential to improve patient care by establishing tests of diagnosis, prognosis, and treatment effects. Successfully translating a biomarker from discovery to clinical application demands high‐quality discovery research and high‐quality clinical studies for biomarker validation; however, there are additional challenges ...
William J, Savage, Allen D, Everett
openaire +2 more sources
From biomarker strategies to biomarker activities and back
Drug Discovery Today, 2010The pharmaceutical industry must find ways to improve the unacceptably high attrition rate during drug development. Clearly, pharma has moved away from treat-and-see testing of new drugs in patients, with a strong current focus on generating translational biomarkers early in the research process to enable more predictive evaluation of drug action in ...
Gool, A.J. van +2 more
openaire +4 more sources
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 1988
Abstract This article presents a conceptual discussion of some aspects involved in biomarkers in aging. A biomarker of aging is a biological parameter of an organism that either alone or in some multivariate composite will, in the absence of disease, better predict functional capability at some late age than will chronological age.
openaire +3 more sources
Abstract This article presents a conceptual discussion of some aspects involved in biomarkers in aging. A biomarker of aging is a biological parameter of an organism that either alone or in some multivariate composite will, in the absence of disease, better predict functional capability at some late age than will chronological age.
openaire +3 more sources
Thoracic Surgery Clinics, 2020
Immune checkpoint inhibitor (ICI) therapy has been approved for several solid tumors, including non-small cell lung cancer. ICIs have shown unprecedented durable responses and higher response rates than chemotherapy in selected patients. The development of biomarkers that serve as predictors of response is crucial for treatment selection.
Jean G, Bustamante-Alvarez +1 more
openaire +2 more sources
Immune checkpoint inhibitor (ICI) therapy has been approved for several solid tumors, including non-small cell lung cancer. ICIs have shown unprecedented durable responses and higher response rates than chemotherapy in selected patients. The development of biomarkers that serve as predictors of response is crucial for treatment selection.
Jean G, Bustamante-Alvarez +1 more
openaire +2 more sources
Critical Care Clinics, 2018
A biomarker is a characteristic by which a (patho)physiologic process can be identified. Biomarkers can be of diagnostic value (to discriminate infection from noninfectious conditions or to determine the causative pathogen), of prognostic value (assigning risk profiles and predict outcome), and in the future may be of theranostic value (aid in ...
van Engelen, Tjitske S. R. +3 more
openaire +3 more sources
A biomarker is a characteristic by which a (patho)physiologic process can be identified. Biomarkers can be of diagnostic value (to discriminate infection from noninfectious conditions or to determine the causative pathogen), of prognostic value (assigning risk profiles and predict outcome), and in the future may be of theranostic value (aid in ...
van Engelen, Tjitske S. R. +3 more
openaire +3 more sources